{"denoms":[{"counts":[{"groupId":"BG000","value":"538"}],"units":"Participants"}],"groups":[{"description":"Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.","id":"BG000","title":"Tocilizumab 8 mg/kg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.03","value":"50.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"443"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"95"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"All-exposure population: All patients who entered the study and received at least one dose of tocilizumab at any time. Baseline was defined as the first dose of study drug, whether that occurred in the WA17822 study or the WA18695 study."}